<DOC>
	<DOCNO>NCT00000553</DOCNO>
	<brief_summary>To measure effect lipid-lowering drug and/or antioxidant vitamin progression regression coronary heart disease measure quantitative angiography patient low high density lipoprotein ( HDL ) cholesterol .</brief_summary>
	<brief_title>HDL-Atherosclerosis Treatment Study ( HATS )</brief_title>
	<detailed_description>BACKGROUND : More one-third patient coronary disease `` low '' high density lipoprotein cholesterol ( HDLc ) level ( less 35 mg/dl ; United States 20th percentile ) `` normal '' low density lipoprotein cholesterol ( LDLc ) ( le 145 ; United States mean ) , group current treatment guideline base clinical trial data . Low HDLc level strong , independent predictor cardiovascular disease cardiovascular mortality risk , equally men woman . This high coronary artery disease risk may due imbalance delivery cholesterol arterial intima LDL removal HDL . Also , since HDL serve antioxidant cytoprotectants , important HDL role may prevent LDL oxidation thus limit macrophage-mediated intimal lipid accumulation prevent vascular cell toxicity . Recent epidemiologic , experimental , clinical trial evidence suggest 15 mg/dl rise HDL cholesterol would reduce coronary artery disease incidence mortality 30 70 percent antioxidant vitamin E , C , beta-carotene might reduce coronary artery disease event atherogenesis . The potential absolute benefit much great exist coronary artery disease . It also show HDLc rise response exercise , smoke cessation , weight reduction , monounsaturated fat . DESIGN NARRATIVE : Randomized , Phase III . Each patient randomly assign lipid-altering strategy placebo antioxidant vitamin strategy placebo , 2 x 2 factorial design . The four group simvastatin-niacin plus antioxidant vitamin cocktail ; simvastatin-niacin plus vitamin placebo ; antioxidant vitamin alone plus simvastatin-niacin placebo ; placebo strategy . All group counsel respect diet , exercise , smoke cessation . The primary endpoint average change proximal obstructive disease 2.5 year interval baseline followup study . Secondary endpoint include frequency cardiac event , include cardiac death , confirm non-fatal myocardial infarction , cerebrovascular accident , revascularization bypass angioplasty medically refractory unstable ischemia . The trial end August , 1999 .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Men woman low HDL cholesterol , least one 50 % stenotic coronary lesion three 30 % stenotic coronary lesion . Women range age 35 less 68 men 35 less 63 .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>March 2005</verification_date>
</DOC>